Table 3.
Treatment outcomes and reasons for discontinuation
| ACI | MTX | FAE | CyA | ALI | APR | ADA | ETA | INX | GOL | CER | UST | SEC | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total number of treatment courses, n | 205 | 220 | 96 | 70 | 53 | 35 | 69 | 62 | 32 | 12 | 8 | 42 | 31 |
| Non‐responsea, n (%) | 66 (32.2) | 82 (37.3) | 36 (37.5) | 8 (11.4) | 20 (37.7) | 9 (25.7) | 19 (27.5) | 16 (25.8) | 7 (21.9) | 3 (25.0) | 0 (0.0) | 7 (16.7) | 11 (35.5) |
| Partial responsea, n (%) | 87 (42.4) | 78 (35.5) | 34 (35.4) | 23 (32.9) | 19 (35.9) | 10 (28.6) | 23 (33.3) | 33 (53.2) | 12 (37.5) | 4 (33.3) | 3 (37.5) | 16 (38.1) | 8 (25.8) |
| Excellent responsea, n (%) | 40 (19.5) | 37 (16.8) | 17 (17.7) | 36 (51.4) | 12 (22.6) | 11 (31.4) | 23 (33.3) | 12 (19.4) | 13 (40.6) | 5 (41.7) | 5 (62.5) | 13 (31.0) | 9 (29.0) |
| Treatment discontinued, n (%) | 156 (76.1) | 175 (79.6) | 80 (83.3) | 60 (85.7) | 39 (73.6) | 14 (40.0) | 47 (68.1) | 52 (83.9) | 20 (62.5) | 6 (50.0) | 1 (12.5) | 21 (50.0) | 18 (58.1) |
| ▸Adverse eventsb, n (%) | 93 (59.6) | 72 (41.1) | 55 (68.8) | 28 (46.7) | 11 (28.2) | 4 (28.6) | 18 (38.3) | 11 (21.2) | 9 (45.0) | 1 (16.7) | 1 (100) | 3 (14.3) | 2 (11.1) |
| ▸Ineffectiveness skinb, n (%) | 83 (53.2) | 96 (54.9) | 28 (35.0) | 14 (23.3) | 29 (74.4) | 8 (57.1) | 30 (63.8) | 36 (69.2) | 11 (55.0) | 3 (50.0) | 1 (100) | 14 (66.7) | 12 (66.7) |
| ▸Ineffectiveness jointsb, n (%) | 9 (5.8) | 30 (17.1) | 2 (2.5) | 1 (1.7) | 0 (0.0) | 2 (14.3) | 16 (34.0) | 22 (42.3) | 3 (15.0) | 5 (83.3) | 1 (100) | 9 (42.9) | 2 (11.1) |
| ▸Remissionb, n (%) | 5 (3.2) | 7 (4.0) | 7 (8.8) | 9 (15.0) | 6 (15.4) | 0 (0.0) | 0 (0.0) | 1 (1.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.8) | 0 (0.0) |
a
Response was evaluated at the end of treatment or time of last observation according to physician's description and/or photographic evidence.
b
Percentage of all patients who discontinued the respective treatment. Multiple reasvons could be stated.
Abbr.: ACI, acitretin; MTX, methotrexate; FAE, fumaric acid esters; CyA, cyclosporine A; ALI, alitretinoin; APR, apremilast; ADA, adalimumab; ETA, etanercept; INX, infliximab; GOL, golimumab; CER, certolizumab pegol; UST, ustekinumab; SEC, secukinumab.